S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

Relmada Therapeutics Stock Forecast, Price & News

+1.13 (+6.03%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
101,934 shs
Average Volume
168,610 shs
Market Capitalization
$524.36 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Relmada Therapeutics logo

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It focuses on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist, which is a New Chemical Entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in Coral Gables, FL.


Relmada Therapeutics (NASDAQ:RLMD) Shares Up 5.8%
January 14, 2022 |  americanbankingnews.com
Relmada Therapeutics (NASDAQ:RLMD) Trading 7.3% Higher
December 23, 2021 |  americanbankingnews.com
RLMD.O - Relmada Therapeutics Inc Profile | Reuters
December 10, 2021 |  reuters.com
Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022
October 20, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$6.50 per share


Net Income
$-59.46 million
Pretax Margin




Free Float
Market Cap
$524.36 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.06 out of 5 stars

Medical Sector

545th out of 1,417 stocks

Pharmaceutical Preparations Industry

257th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Relmada Therapeutics (NASDAQ:RLMD) Frequently Asked Questions

Is Relmada Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Relmada Therapeutics stock.
View analyst ratings for Relmada Therapeutics
or view top-rated stocks.

How has Relmada Therapeutics' stock been impacted by Coronavirus?

Relmada Therapeutics' stock was trading at $40.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RLMD shares have decreased by 50.6% and is now trading at $19.86.
View which stocks have been most impacted by COVID-19

Are investors shorting Relmada Therapeutics?

Relmada Therapeutics saw a increase in short interest in December. As of December 31st, there was short interest totaling 1,360,000 shares, an increase of 40.7% from the December 15th total of 966,900 shares. Based on an average daily volume of 158,100 shares, the short-interest ratio is currently 8.6 days. Currently, 8.6% of the company's stock are short sold.
View Relmada Therapeutics' Short Interest

When is Relmada Therapeutics' next earnings date?

Relmada Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for Relmada Therapeutics

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics, Inc. (NASDAQ:RLMD) posted its earnings results on Thursday, November, 11th. The company reported ($2.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.62) by $0.82.
View Relmada Therapeutics' earnings history

What price target have analysts set for RLMD?

6 equities research analysts have issued 1-year price targets for Relmada Therapeutics' shares. Their forecasts range from $24.55 to $90.00. On average, they anticipate Relmada Therapeutics' share price to reach $56.91 in the next twelve months. This suggests a possible upside of 186.6% from the stock's current price.
View analysts' price targets for Relmada Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Relmada Therapeutics' key executives?

Relmada Therapeutics' management team includes the following people:
  • Sergio Traversa, Chief Executive Officer & Director
  • Maged S. Shenouda, Chief Financial Officer
  • Gina DiGuglielmo, Vice President & Head-Clinical Operations
  • Marco Pappagallo, Chief Medical Officer
  • Paolo Manfredi, Chief Scientific Officer

What is Relmada Therapeutics' stock symbol?

Relmada Therapeutics trades on the NASDAQ under the ticker symbol "RLMD."

How do I buy shares of Relmada Therapeutics?

Shares of RLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Relmada Therapeutics' stock price today?

One share of RLMD stock can currently be purchased for approximately $19.86.

How much money does Relmada Therapeutics make?

Relmada Therapeutics has a market capitalization of $524.36 million. The company earns $-59.46 million in net income (profit) each year or ($6.62) on an earnings per share basis.

How many employees does Relmada Therapeutics have?

Relmada Therapeutics employs 14 workers across the globe.

What is Relmada Therapeutics' official website?

The official website for Relmada Therapeutics is www.relmada.com.

Where are Relmada Therapeutics' headquarters?

Relmada Therapeutics is headquartered at 880 Third Avenue 12th Floor, NEW YORK NY, 10022.

How can I contact Relmada Therapeutics?

Relmada Therapeutics' mailing address is 880 Third Avenue 12th Floor, NEW YORK NY, 10022. The company can be reached via phone at (646) 876-3459 or via email at [email protected].

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.